Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients

BACKGROUND: Biological therapies have revolutionized the treatment of patients with inflammatory bowel disease (IBD). Infliximab (IFX) has been shown to be effective in inducing and maintaining remission in patients with Crohn’s disease and ulcerative colitis. However, about one-third of the patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Camilla de Almeida, de Azevedo, Matheus Freitas Cardoso, Carlos, Alexandre Sousa, Damião, Aderson Omar Mourão Cintra, Sobrado Junior, Carlos Walter, Nahas, Sergio Carlos, Queiroz, Natália Sousa Freitas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
IBD Barriers Across the Continents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652804/
https://www.ncbi.nlm.nih.gov/pubmed/38026104
http://dx.doi.org/10.1177/17562848231210053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652804/
https://www.ncbi.nlm.nih.gov/pubmed/38026104
http://dx.doi.org/10.1177/17562848231210053

Ejemplares similares